Your browser doesn't support javascript.
Vaccine-induced seroconversion in participants in the North Carolina COVID-19 community Research Partnership.
Friedman-Klabanoff, DeAnna J; Tjaden, Ashley H; Santacatterina, Michele; Munawar, Iqra; Sanders, John W; Herrington, David M; Wierzba, Thomas F; Berry, Andrea A.
  • Friedman-Klabanoff DJ; Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA. Electronic address: defriedman@som.umaryland.edu.
  • Tjaden AH; Biostatistics Center, Milken Institute School of Public Health, George Washington University, Rockville, MD, USA.
  • Santacatterina M; Department of Population Health, NYU Grossman School of Medicine, New York, NY, USA.
  • Munawar I; Section on Infectious Diseases, Department of Internal Medicine, Wake Forest School of Medicine, Winston Salem, NC, USA.
  • Sanders JW; Section on Infectious Diseases, Department of Internal Medicine, Wake Forest School of Medicine, Winston Salem, NC, USA.
  • Herrington DM; Section on Cardiology, Department of Internal Medicine, Wake Forest School of Medicine, Winston Salem, NC, USA.
  • Wierzba TF; Section on Infectious Diseases, Department of Internal Medicine, Wake Forest School of Medicine, Winston Salem, NC, USA.
  • Berry AA; Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.
Vaccine ; 40(42): 6133-6140, 2022 10 06.
Article in English | MEDLINE | ID: covidwho-2031731
ABSTRACT
Well-regulated clinical trials have shown FDA-approved COVID-19 vaccines to be immunogenic and highly efficacious. We evaluated seroconversion rates in adults reporting ≥ 1 dose of an mRNA COVID-19 vaccine in a cohort study of nearly 8000 adults residing in North Carolina to validate immunogenicity using a novel

approach:

at-home, participant administered point-of-care testing. Overall, 91.4% had documented seroconversion within 75 days of first vaccination (median 31 days). Participants who were older and male participants were less likely to seroconvert (adults aged 41-65 adjusted hazard ratio [aHR] 0.69 [95% confidence interval (CI) 0.64, 0.73], adults aged 66-95 aHR 0.55 [95% CI 0.50, 0.60], compared to those 18-40; males aHR 0.92 [95% CI 0.87, 0.98], compared to females). Participants with evidence of prior infection were more likely to seroconvert than those without (aHR 1.50 [95% CI 1.19, 1.88]) and those receiving BNT162b2 were less likely to seroconvert compared to those receiving mRNA-1273 (aHR 0.84 [95% CI 0.79, 0.90]). Reporting at least one new symptom after first vaccination did not affect time to seroconversion, but participants reporting at least one new symptom after second vaccination were more likely to seroconvert (aHR 1.11 [95% CI 1.05, 1.17]). This data demonstrates the high community-level immunogenicity of COVID-19 vaccines, albeit with notable differences in older adults, and feasibility of using at-home, participant administered point-of-care testing for community cohort monitoring. Trial registration ClinicalTrials.gov NCT04342884.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccines / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Aged / Female / Humans / Male Country/Region as subject: North America Language: English Journal: Vaccine Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccines / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Aged / Female / Humans / Male Country/Region as subject: North America Language: English Journal: Vaccine Year: 2022 Document Type: Article